ReviewExpert opinion on investigational drugs2010
Future novel therapeutic agents for Clostridium difficile infection.
Review in Expert opinion on investigational drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 39 citations in OpenAlex.
- Characterization of heparin interactions with Clostridioides difficile toxins and its potential as anti-CDI therapeutics.Carbohydrate polymers · 2025Article
- Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection.Microbiology spectrum · 2022Article
- Prevalence, Molecular Characterization and Antimicrobial Susceptibility ofInternational journal of environmental research and public health · 2021Article
- Anti-virulence strategies forGut microbes · 2020Review
- Oral Immunization with Nontoxigenic Clostridium difficile Strains Expressing Chimeric Fragments of TcdA and TcdB Elicits Protective Immunity against C. difficile Infection in Both Mice and Hamsters.Infection and immunity · 2018Article
- Facilely accessible quinoline derivatives as potent antibacterial agents.Bioorganic & medicinal chemistry · 2018Article
- Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile.ChemMedChem · 2018Article
- The roles of host and pathogen factors and the innate immune response in the pathogenesis of Clostridium difficile infection.Molecular immunology · 2015Review
- Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections.Antimicrobial agents and chemotherapy · 2014Article
- Immune-based treatment and prevention of Clostridium difficile infection.Human vaccines & immunotherapeutics · 2014Review
- Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.Current topics in medicinal chemistry · 2014Review
- MBX-500, a hybrid antibiotic with in vitro and in vivo efficacy against toxigenic Clostridium difficile.Antimicrobial agents and chemotherapy · 2012Article
- Review
- Current Status of Nonantibiotic and Adjunct Therapies for Clostridium difficile Infection.Current infectious disease reports · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
importance of the fieldClostridium difficile is the most important definable cause of healthcare acquired diarrhea. The increasing incidence and mortality associated with this enteric pathogen and the significant rate of treatment failures and recurrences with current antibiotics emphasize the need for the discovery of new and improved therapeutic and preventative agents. WHAT THE READER WILL GAIN: We review upcoming novel therapeutic agents and the clinical evidence to support their efficacy in treating C. difficile infection. We also provide an extensive comparison of antimicrobial susceptibilities of C. difficile based on in vitro susceptibilities published in the literature. AREAS COVERED IN THIS REVIEW: This review was conducted by a thorough examination of the public sources, including journals and scientific meeting abstracts, up to February 2009. TAKE HOME MESSAGE: A number of new therapeutic agents are in development and being tested in clinical trials. However, high costs and concerns for resistance may limit the use of these antimicrobials for the treatment of C. difficile infection. Passive and active immunotherapy may have important future roles as therapeutic and preventative strategies for C. difficile infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.